Stay updated on Zimberelimab Combo vs Pembrolizumab with Chemo in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Zimberelimab Combo vs Pembrolizumab with Chemo in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Zimberelimab Combo vs Pembrolizumab with Chemo in NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays site revision v3.8.1 instead of v3.8.0.
    Difference
    0.0%
    Check dated 2026-11-18T02:53:55.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The record now presents the STAR-121 Phase 3 trial of zimberelimab and domvanalimab with chemotherapy versus pembrolizumab with chemotherapy for untreated metastatic non-small cell lung cancer. It includes study design, eligibility criteria, outcome measures, recruitment status, and participating locations.
    Difference
    100%
    Check dated 2026-11-11T02:00:16.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site footer's revision label changed from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-04T00:23:54.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    A general NIH notice about the terminology transition from “Artificial Intelligence” to “Super Intelligence” was added, and the site revision changed from v3.7.1 to v3.7.2. The study record itself remains inaccessible behind a 403 error.
    Difference
    1%
    Check dated 2026-10-21T00:22:18.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The study record page displays a 403 Forbidden response and a Home link instead of study details. The site revision identifier also advances from v3.7.0 to v3.7.1.
    Difference
    0.6%
    Check dated 2026-10-07T00:27:58.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Access to the study details is blocked by a 403 error. The page now shows the site header and a 403 message instead of the trial content.
    Difference
    17%
    Check dated 2026-09-23T00:35:47.000Z thumbnail image

Stay in the know with updates to Zimberelimab Combo vs Pembrolizumab with Chemo in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Zimberelimab Combo vs Pembrolizumab with Chemo in NSCLC Clinical Trial page.